Merck Experimental Therapy Extends Survival in Advanced Endometrial Cancer Trial
Late-stage trial data presented at the ESMO medical congress showed Merck’s experimental targeted drug helped women with advanced endometrial cancer live longer and kept their disease in check versus standard treatment.
Story updates
04:05:38 PM UTC
SquawkNews
The US health regulator has accepted Merck's NYSE:MRK experimental targeted drug for a priority review based on data from a late-stage trial where it extended survival in women with an advanced form of endometrial cancer.The drug, sacituzumab tirumotecan, also known as sac-TMT, delivers a cancer-ki…
Merck's NYSE:MRK experimental targeted drug helped women with advanced endometrial cancer live longer and kept their disease in check compared with standard treatment, according to late-stage trial data presented at the ESMO medical congress.Based on the data, the US health regulator has accepted t…